Unable to display view head.php file not found.
 
American Journal of Medicine
 

Eikelboom - Evidence from the Randomized Trials - Figure 8
Targets of New Interventions

What are the biologic targets for these new NOACs?  Figure 8 shows the coagulation pathway where the trigger of coagulation is tissue injury and the exposure of tissue factor to the blood, as reviewed in the presentation by Dr.  Weitz[5,6]  Unlike warfarin and heparin, which target multiple coagulation proteins, the NOACs rivaroxaban and apixaban selectively target factor Xa, and the other class of NOAC, represented by dabigatran, selectively targets thrombin.  Eikelboom J. Am J Med 2013; published on-line at http://education.amjmed.com/00000. 

References

[5] Weitz JI, Bates SM. New anticoagulants. J Thromb Haemost. 2005;3:1843-1853.

[6] Weitz JI, Hirsh J, Samama MM; American College of Chest Physicians. New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 Suppl):234S-256S.

Unable to display view foot.php file not found.